Skip to main content
Caplight Logo









EuBiome

EuBiome

Private
ItalyHealthcare & Life Scienceshttps://www.eubiome.it/en/

Last Round

Grant

Nov 9, 2023

Total Funding Raised

$389,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

EuBiome operates in Healthcare & Life Sciences and is based in Italy. Its latest recorded funding round was a Grant round in November 2023.

EuBiome is a biotechnology company that provides microbiome analysis and fecal microbiota transplantation products and services for pets.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Healthcare Analytics, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

EuBiome Comparables

Compare EuBiome with similar companies based on industry and business-model similarity.

EuBiome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AnimalBiome
81%
Amend Pet
80%
MiDOG Animal Diagnostics
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

EuBiome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 9, 2023
GrantJul 7, 2023
CrowdfundingDec 20, 2022
GrantDec 20, 2020
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

EuBiome Investors

Notable investors and investment history

EuBiome investors
InvestorRounds
Regione del VenetoGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 37% MoM.

  • Jun 25, 2026

    Grew 44% QoQ, from 9 to 13 employees.

Book a demo to see all signals

For institutional investors. Book with your work email.

EuBiome Filings

Explore SEC and related filing metadata, where available.

EuBiome filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about EuBiome's valuation, stock price, and market status.

Is EuBiome a public or private company?

EuBiome is a private company.

What is the current stock price of EuBiome?

EuBiome is a private company, so its shares have no public market price. Caplight tracks EuBiome's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is EuBiome worth (valuation)?

Valuation information for EuBiome is not publicly available.

Can I buy EuBiome stock?

EuBiome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was EuBiome's last funding round?

EuBiome's most recent funding round was Grant on November 9, 2023.

Who are the main investors in EuBiome?

Key investors in EuBiome include Regione del Veneto.

Will EuBiome IPO soon?

No public IPO plans have been announced for EuBiome.

How can I track EuBiome secondary market activity?

Caplight tracks bids, offers, and trades in EuBiome's shares on secondary markets.

Firmographic Details

HeadquartersItaly
Employee Range9
Year Founded2019
Last FundingNov 9, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?